Literature DB >> 16569383

The diagnosis and treatment of depression in Parkinson's disease.

William M McDonald1, Paul E Holtzheimer, Eve H Byrd.   

Abstract

Depression is common in Parkinson's disease (PD) and associated with considerable morbidity, including a worsening of motor symptoms and measures of quality of life. Therefore, patients with PD should be routinely screened for depressive symptoms with rating scales such as the Geriatric Depression Scale. Patients meeting criteria should be treated using established algorithms for the management of depression and associated symptoms such as insomnia, anxiety, psychosis, and mania. The algorithm outlined in this paper describes the importance of maintaining an adequate dose of medication over a medication trial that can last up to 12 weeks. To optimally monitor patients' progress, clinicians should also consider using rating scales that measure depression severity, such as the Montgomery-Asberg Depression Rating Scale and Beck Depression Inventory.

Entities:  

Year:  2006        PMID: 16569383     DOI: 10.1007/s11940-006-0015-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  25 in total

1.  The incidence of Parkinson's disease in the Netherlands: results from a longitudinal general practice-based registration.

Authors:  Albert F G Leentjens; Marjan Van den Akker; Job F M Metsemakers; Jaap Troost
Journal:  Neuroepidemiology       Date:  2003 Sep-Oct       Impact factor: 3.282

2.  Validity of the 30-item geriatric depression scale in patients with Parkinson's disease.

Authors:  William M McDonald; Paul E Holtzheimer; Michael Haber; Jerrold L Vitek; Kimberly McWhorter; Mahlon Delong
Journal:  Mov Disord       Date:  2006-10       Impact factor: 10.338

Review 3.  A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders.

Authors:  Marcelo Feijo de Mello; Jair de Jesus Mari; Josue Bacaltchuk; Helen Verdeli; Richard Neugebauer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

4.  Non-recognition of depression and other non-motor symptoms in Parkinson's disease.

Authors:  L M Shulman; R L Taback; A A Rabinstein; W J Weiner
Journal:  Parkinsonism Relat Disord       Date:  2002-01       Impact factor: 4.891

5.  Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm.

Authors:  B H Mulsant; G S Alexopoulos; C F Reynolds; I R Katz; R Abrams; D Oslin; H C Schulberg
Journal:  Int J Geriatr Psychiatry       Date:  2001-06       Impact factor: 3.485

6.  The quality of life in Parkinson's disease.

Authors:  A M Kuopio; R J Marttila; H Helenius; M Toivonen; U K Rinne
Journal:  Mov Disord       Date:  2000-03       Impact factor: 10.338

7.  Factors of importance to the caregiver burden experienced by family caregivers of Parkinson's disease patients.

Authors:  Marianne Caap-Ahlgren; Ove Dehlin
Journal:  Aging Clin Exp Res       Date:  2002-10       Impact factor: 3.636

8.  Recognition and treatment of depression in Parkinson's disease.

Authors:  Daniel Weintraub; Paul J Moberg; John E Duda; Ira R Katz; Matthew B Stern
Journal:  J Geriatr Psychiatry Neurol       Date:  2003-09       Impact factor: 2.680

Review 9.  Prevalence, etiology, and treatment of depression in Parkinson's disease.

Authors:  William M McDonald; Irene H Richard; Mahlon R DeLong
Journal:  Biol Psychiatry       Date:  2003-08-01       Impact factor: 13.382

10.  The motor performance test series in Parkinson's disease is influenced by depression.

Authors:  W Kuhn; N Heye; T Müller; P Kraus; P Klotz; B Friedrich; F L Welter; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

View more
  2 in total

1.  Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models.

Authors:  Elena L Paley; Galina Denisova; Olga Sokolova; Natalia Posternak; Xukui Wang; Anna-Liisa Brownell
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

2.  Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia.

Authors:  E R Bychkov; V V Gurevich; J N Joyce; J L Benovic; E V Gurevich
Journal:  Neurobiol Aging       Date:  2006-11-27       Impact factor: 4.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.